Sarepta soars after being notified by the FDA the company may lift its voluntary pause on shipments of Elevidys for ...

Sarepta Therapeutics stock is surging nearly 50% after the Food and Drug Administration told the company it can [lift a voluntary pause on shipments of Elevidys](http ...

Despite all the buzz around Sarepta and concerns about Elevidys, industry watchers aren’t convinced this current controversy ...

Sarepta stock jumped after the drugmaker resumed shipments of the medicine Elevidys, previously paused by request by the FDA, ...

As the market awaits key catalysts that would play out over the next couple of sessions, the following stocks saw brisk ...

Sarepta Therapeutics said it will resume shipments of its gene therapy Elevidys® (delandistrogene moxeparvovec-rokl) “imminently” to ambulant patients with Duchenne muscular dystrophy (DMD), ending a ...

The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.

The FDA has lifted its hold on Elevidys for ambulatory patients, after asking Sarepta to pause the treatment following three deaths.

Brown University took out another private loan, securing a $500 million agreement after the Ivy League school warned of “deep ...

Sarepta Therapeutics said on Monday it will resume shipping of its gene therapy Elevidys to patients with a rare muscular ...

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping ...

The swift FDA action removes an overhang from Sarepta and allows Elevidys to return to the market without another safety ...